BIO 2025

Citius Oncology, Inc., an oncology-focused subsidiary of Citius Pharmaceuticals, a late-stage biopharma company developing and commercializing first-in-class critical care products, has entered into a distribution services agreement with Cardinal Health, a provider of pharmaceutical and specialty pharmaceutical distribution services in the U.S.

This agreement is designed to help provide access to LYMPHIR (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.

Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.

“This agreement marks a key step forward in our launch readiness efforts,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. “Cardinal Health’s proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network.”